Lilly’s Taltz wins third approval, this time in patients with active ankylosing spondylitis
Lilly’s Taltz wins third approval, this time in patients with active ankylosing spondylitis
taltz
Lilly Announces Positive Results for Two Phase 3 Studies of Taltz (ixekizumab) in Ankylosing Spondylitis
https://www.biospace.com/article/releases/acr-2018-lilly-announces-positive-results-for-two-phase-3-studies-of-taltz-ixekizumab-in-ankylosing-spondylitis-radiographic-axial-spondyloarthritis-/
ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
